NASDAQ:AMPH - Amphastar Pharmaceuticals Stock Price, Price Target & More

Amphastar Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMPH."

Amphastar Pharmaceuticals declared that its board has approved a share repurchase program on Thursday, August 10th 2017, which permits the company to repurchase $20,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to repurchase up to 2.8% of its stock through open market purchases. Stock repurchase programs are generally an indication that the company's board of directors believes its stock is undervalued.

Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) released its quarterly earnings data on Wednesday, May, 9th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.08 by $0.13. The firm had revenue of $58.40 million for the quarter, compared to analysts' expectations of $60.75 million. Amphastar Pharmaceuticals had a negative net margin of 1.50% and a positive return on equity of 3.39%. The business's revenue was up 3.0% compared to the same quarter last year. During the same quarter last year, the firm posted $0.09 EPS. View Amphastar Pharmaceuticals' Earnings History.

6 Wall Street analysts have issued 12-month price targets for Amphastar Pharmaceuticals' stock. Their forecasts range from $18.00 to $26.00. On average, they expect Amphastar Pharmaceuticals' stock price to reach $21.20 in the next year. This suggests a possible upside of 29.1% from the stock's current price. View Analyst Ratings for Amphastar Pharmaceuticals.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amphastar Pharmaceuticals in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Amphastar Pharmaceuticals include The Medicines (MDCO), Blueprint Medicines (BPMC), Amicus Therapeutics (FOLD), Ascendis Pharma A/S (ASND), Horizon Pharma (HZNP), Heron Therapeutics (HRTX), Intercept Pharmaceuticals (ICPT), Evotec (EVTCY), Supernus Pharmaceuticals (SUPN), Emergent Biosolutions (EBS), Portola Pharmaceuticals (PTLA), Akcea Therapeutics (AKCA), Clovis Oncology (CLVS), Spectrum Pharmaceuticals (SPPI) and Endo International (ENDP).

News stories about AMPH stock have been trending positive on Wednesday, Accern reports. Accern identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Amphastar Pharmaceuticals earned a media sentiment score of 0.36 on Accern's scale. They also assigned news headlines about the company an impact score of 46.64 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Amphastar Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Fisher Asset Management LLC (0.28%). Company insiders that own Amphastar Pharmaceuticals stock include Diane G Gerst, Floyd F Petersen, Howard Lee, Jack Y Zhang, Jason B Shandell, Michael A Zasloff, Richard K Prins, Rong Zhou, Stephen B Shohet and William J Peters. View Institutional Ownership Trends for Amphastar Pharmaceuticals.

AMPH stock was sold by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC. Company insiders that have sold Amphastar Pharmaceuticals company stock in the last year include Diane G Gerst, Floyd F Petersen, Jason B Shandell, Michael A Zasloff, Richard K Prins, Stephen B Shohet and William J Peters. View Insider Buying and Selling for Amphastar Pharmaceuticals.

Shares of AMPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of AMPH stock can currently be purchased for approximately $16.42.

Amphastar Pharmaceuticals has a market capitalization of $755.61 million and generates $240.18 million in revenue each year. The company earns $4.50 million in net income (profit) each year or $0.38 on an earnings per share basis. Amphastar Pharmaceuticals employs 1,644 workers across the globe.

Amphastar Pharmaceuticals' mailing address is 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730. The company can be reached via phone at 909-980-9484 or via email at [email protected]